Tejara Capital Ltd Has $994,000 Position in Humana Inc. $HUM

Tejara Capital Ltd lessened its holdings in Humana Inc. (NYSE:HUM) by 46.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,880 shares of the insurance provider’s stock after selling 3,320 shares during the quarter. Tejara Capital Ltd’s holdings in Humana were worth $994,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. Montag A & Associates Inc. boosted its position in shares of Humana by 1,880.0% during the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock valued at $25,000 after acquiring an additional 94 shares in the last quarter. CoreCap Advisors LLC increased its stake in Humana by 54.4% in the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 37 shares during the period. Rosenberg Matthew Hamilton raised its position in Humana by 136.0% in the fourth quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after purchasing an additional 68 shares in the last quarter. Larson Financial Group LLC lifted its stake in Humana by 114.1% during the third quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider’s stock worth $40,000 after purchasing an additional 81 shares during the period. Finally, Fulcrum Asset Management LLP bought a new position in Humana during the third quarter worth about $42,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insider Activity

In related news, insider Sanjay K. Shetty purchased 810 shares of Humana stock in a transaction that occurred on Monday, February 23rd. The shares were acquired at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the transaction, the insider directly owned 11,657 shares in the company, valued at approximately $2,158,992.97. This represents a 7.47% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

HUM has been the topic of several analyst reports. Mizuho upped their price objective on Humana from $258.00 to $290.00 in a research note on Thursday, April 30th. Morgan Stanley set a $146.00 price target on Humana in a research note on Thursday, February 12th. Wells Fargo & Company upped their price target on Humana from $206.00 to $227.00 and gave the company an “equal weight” rating in a research report on Tuesday, April 7th. Truist Financial increased their price objective on Humana from $220.00 to $270.00 and gave the stock a “hold” rating in a research note on Thursday, April 30th. Finally, TD Cowen lifted their price objective on Humana from $173.00 to $211.00 and gave the company a “hold” rating in a report on Friday, May 1st. Seven research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $246.83.

Humana Stock Down 1.4%

Shares of HUM opened at $300.52 on Friday. The company has a market capitalization of $36.08 billion, a P/E ratio of 32.14, a PEG ratio of 2.82 and a beta of 0.68. Humana Inc. has a one year low of $163.11 and a one year high of $315.35. The business’s 50 day simple moving average is $202.73 and its 200-day simple moving average is $226.49. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.77 and a quick ratio of 1.77.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share for the quarter, beating analysts’ consensus estimates of $9.97 by $0.34. Humana had a return on equity of 10.45% and a net margin of 0.82%.The firm had revenue of $39.65 billion during the quarter, compared to analysts’ expectations of $39.37 billion. During the same period last year, the firm posted $11.58 EPS. The business’s revenue was up 23.5% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000- EPS. As a group, sell-side analysts predict that Humana Inc. will post 9.06 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be paid a $0.885 dividend. The ex-dividend date is Friday, June 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. Humana’s dividend payout ratio (DPR) is 37.86%.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.